The next Gilman Scholarship deadline for study abroad is 25 February 2027, after the fall 2026 cycle closed on 1 October, according to the programme’s deadlines page. Applications for the spring cycle open in mid-January 2027.
The spring 2027 cycle has a student deadline of 25 February 2027 at 11:59 pm Pacific Time, an advisor certification deadline of 4 March 2027 and notification in May 2027. It covers programmes starting between 1 May 2027 and 30 April 2028. The fall 2026 cycle closed on 1 October; its notifications are due in December. Late applications are not accepted.
Who can apply
This is a US programme. Per the eligibility page, applicants must be US citizens or nationals, undergraduates at an accredited US institution, receiving a Federal Pell Grant when they apply or able to show they will during their term, and applying to or accepted into a credit-bearing study abroad or internship programme.
Where you can go
The destination must have an overall Travel Advisory Level 1 or 2, and areas rated Level 3 or 4 are off-limits. Programmes at institutions on the Section 1286 NDAA list are barred; the page says the list dated 26 June 2026 applies to programmes in China. Recipients can receive the award only once.
Planning your application
Choose the cycle matching your programme dates, and remember advisor certification is a separate, later deadline. Award amounts are on the programme overview page, not the pages we reviewed. If you are not a US student, see our guides to Erasmus Mundus and Commonwealth scholarships, and check your options with our visa eligibility checker.
Gilman Scholarship FAQ
When is the next Gilman deadline?
25 February 2027 at 11:59 pm Pacific Time for the spring cycle.
Is the Gilman Scholarship open to international students?
No. Applicants must be US citizens or nationals studying at US institutions.
Do I need a Pell Grant?
Yes, you must receive one when applying or prove you will during your study abroad term.
Can I use it anywhere?
Only in locations with a Level 1 or 2 travel advisory, and not at barred institutions.
Hackers broke into Denmark’s national population register. They pulled records on about 8.8 million people, Danish authorities said on October 5, 2026. That is more than Denmark’s entire population of roughly 6 million. The Denmark CPR data breach exposed records going back years, including people who have died or moved abroad. Names, home addresses and national ID numbers were all exposed.
What the Denmark CPR Data Breach Exposed
The Central Person Register, known as the CPR, is Denmark’s core identity database. It assigns every resident a personal ID number. That number gets used across healthcare, banking, taxes and government services. Cybernews’ reporting on the incident says attackers used access credentials that belonged to a private Danish company to search the register. The register itself holds roughly 11 million records. That explains why a breach of 8.8 million entries can outnumber the country’s living population.
People already enrolled in Denmark’s name and address protection scheme were not affected, officials said. Everyone else had their name, home address and CPR number exposed. Whoever misused that stolen access now holds that information.
Why a National ID Breach Hits Differently Than a Typical Hack
Most consumer data breaches expose usernames, emails or card numbers. Those can usually be changed after a breach. A CPR number cannot be changed. It follows a Danish resident for life. It links medical records, tax filings, pension accounts and government correspondence together. That permanence is exactly why Denmark’s Minister of Research, Education and Digitalization, Christina Egelund, called the incident “a deeply serious incident.” She urged citizens to stay alert “now and in the future,” according to ITPro’s account of the government’s response.
Denmark’s MitID two-factor login system should stop attackers from directly impersonating someone using a CPR number alone. Still, officials warned residents to expect a wave of phishing attempts. Fake texts, calls and emails may come from people posing as banks or government agencies. Those scammers already know their target’s name, address and ID number. That makes the scam far more convincing than an ordinary phishing attempt would be.
What Security Researchers Say Went Wrong at the CPR
The breach traces back to legitimate access, not a software flaw. A private company had standing permission to search the CPR system. Attackers appear to have hijacked that access rather than breaking in directly. Cybersecurity researchers quoted by ITPro flagged two separate problems with that setup. One researcher pointed to the lag between when the intrusion began in September and when staff first noticed irregular activity. That activity surfaced on the night of Friday, October 2. The researcher called that detection gap a common weakness whenever a breach arrives through a third party. Another researcher warned that centralized national databases carry outsized risk whenever outside partners get direct search access. That expert recommended stricter limits on what partners can view, paired with monitoring for unusual search patterns.
Denmark is not the first European country to face a breach of this scale. Government identity systems have become frequent targets. A single successful intrusion can expose data on nearly an entire population at once. European data protection law requires member states to report major breaches quickly. It also requires them to notify affected individuals when the risk is high. Danish officials have not yet said whether every affected resident will get an individual notice, or only a general public warning.
Denmark has reported the incident to its national data protection authority. Police are now investigating alongside other agencies. The government has not named the company whose access was exploited. It has not identified any suspects either.
How Denmark Is Responding to the CPR Data Breach Now
Officials revoked the abused access credentials. They say they have added new protections to the CPR system since. A broader security review is underway across government agencies that rely on the register. Denmark’s response mirrors a pattern now familiar across the tech industry. Companies and governments alike are tightening data access, even as they rethink how they screen for vulnerabilities in increasingly complex systems.
The incident also lands amid wider scrutiny of how technology platforms handle sensitive data and automated systems. That theme surfaced days earlier at a city council hearing on AI governance in New York. It surfaced again in an unrelated trade secrets dispute between Apple and OpenAI set for mid-October. None of those cases involve the Danish breach directly. But they reflect a broader year in which lawmakers and regulators on both sides of the Atlantic have pushed harder on how data gets stored, shared and protected.
For now, Danish residents have been told to avoid sharing passwords or one-time login codes with anyone who contacts them unexpectedly. That holds true even if the caller already knows personal details. Security firms recommend verifying any unexpected request through an official phone number or website, rather than a number the caller provides.
Denmark Data Breach: What People Are Asking
How many people were affected by the Denmark CPR data breach?
About 8.8 million records were accessed, out of roughly 11 million total entries in the register. Those entries include deceased people and former residents.
What information was exposed?
Names, home addresses and CPR numbers, Denmark’s national ID number, were exposed. People enrolled in the country’s address protection program were excluded from the exposure.
How did hackers get into the system?
They used access credentials belonging to a private Danish company. That company had legitimate permission to search the register, so this was not a technical break-in.
When was the breach discovered?
Irregular activity was first spotted on the night of Friday, October 2, 2026. The government confirmed the scope of the breach and went public on October 5.
Can someone use a stolen CPR number to steal my identity?
Denmark’s MitID two-factor system limits that risk. Still, officials warned residents to watch for phishing calls, texts and emails from people who already know their personal details.
Has anyone been identified as responsible for the breach?
No. Officials had not named a suspect as of their statements. They had not confirmed whether the breach originated from a criminal group or another source.
Shionogi agreed on October 5, 2026, to pay $2 billion in cash for IntraBio. IntraBio is a small, privately held biotech based in Austin, Texas. The Shionogi IntraBio rare disease deal hands the Japanese drugmaker a medicine that treats two separate ultra-rare, often fatal genetic disorders. It also brings a pipeline aimed at a handful of other conditions most people have never heard of.
What the Shionogi IntraBio Rare Disease Deal Actually Buys
IntraBio’s lead product, Aqneursa, won U.S. approval in 2024 for Niemann-Pick disease type C. That is a rare neurodegenerative disorder. Late last month, the FDA cleared the same drug for a second use: ataxia-telangiectasia. That is a genetic condition that damages the nervous system and immune system from early childhood. Fierce Pharma’s reporting on the deal notes that Aqneursa is now the first approved treatment for ataxia-telangiectasia anywhere in the world.
IntraBio reported $68 million in sales for 2025. That is a modest figure next to the $2 billion price tag Shionogi just agreed to pay. Shionogi is clearly paying for more than current revenue. It gets IntraBio’s rare-disease development team. It also gets a pipeline that includes a Phase 3 program for CACNA1A-related disorders. Shionogi estimates that group of neurological conditions affects about 30,000 people in the United States, and none currently have an approved treatment.
Why a Tiny Patient Population Still Commands a Big Price
Rare-disease drugs often carry prices most consumers would find startling. So few patients exist to share the cost of development that each one effectively pays more. Regulators also tend to move faster on these approvals than on mainstream drugs. Insurers rarely push back hard on reimbursement once a treatment becomes the only option on the market. That combination makes ultra-rare disease drugs attractive to acquirers, even when the current sales base looks small.
The U.S. Food and Drug Administration grants orphan drug status to treatments for conditions affecting fewer than 200,000 Americans. That status comes with tax credits and extended market exclusivity. Aqneursa qualifies for both of its approved uses. Those protections make the economics of ultra-rare disease drugs more predictable for a buyer like Shionogi. They also help explain why competition for approved orphan drugs has intensified across the pharmaceutical industry this year.
A Rare Disease Deal Fits a Wider Pattern in Pharma
Shionogi built much of its business on antibiotics and antiviral drugs. It has spent the past two years trying to diversify away from that base. In April, it paid $2.5 billion for Tanabe Pharma’s Radicava, a treatment for ALS. Shionogi projects Radicava could reach $700 million in annual sales. BioPharma Dive’s coverage of the IntraBio deal notes that Shionogi plans to apply IntraBio’s regulatory and commercial expertise across its wider rare-disease pipeline. That pipeline includes programs targeting Pompe disease and Fragile X syndrome.
Shionogi is not alone in chasing rare-disease assets this month. Novartis struck its own rare-disease and oncology licensing agreement with China’s Abogen Biosciences just days earlier. That deal is part of a broader wave of pharma dealmaking. It has continued even as bank earnings season dominates the wider market’s attention this week. Large drugmakers increasingly prefer buying proven, approved rare-disease treatments over gambling on early-stage pipelines. A drug already on the market simply carries far less regulatory risk.
Shionogi’s chief executive, Isao Teshirogi, framed the purchase as a natural extension of the company’s history. He said the deal reflects Shionogi’s “solid commitment to building a leading global rare disease business.” He pointed to the company’s track record with infectious diseases as the model for its approach to rare conditions now. Nathan McCutcheon, head of Shionogi’s U.S. subsidiary, said the acquisition would help “accelerate the development of new treatment options.” He noted that patients with these conditions often wait years for any approved therapy at all.
What Still Has to Happen Before the Deal Closes
IntraBio will become a wholly owned subsidiary of Shionogi’s New Jersey-based U.S. division once the transaction completes. Shionogi said it will review how the acquisition affects its financial outlook for the fiscal year ending next March. That language signals Shionogi has not yet folded IntraBio’s numbers into its own guidance. Neither company has disclosed a target closing date. Neither has detailed the payment structure beyond describing it as an all-cash transaction. The announcement follows a busy week for large corporate transactions, including the completed Paramount-Warner Bros. Discovery merger in media.
The deal still needs standard antitrust clearance. IntraBio’s narrow patient base makes a competition challenge unlikely, though. Investors will be watching Shionogi’s next earnings update closely. They want guidance on how quickly Aqneursa’s second approved use can add meaningfully to sales. They will also want to know whether the CACNA1A pipeline advances on schedule toward a possible future filing.
Shionogi-IntraBio Deal: Fast Facts
How much is Shionogi paying for IntraBio?
$2 billion in cash, according to both companies’ statements on October 5, 2026.
What does IntraBio’s drug Aqneursa treat?
It treats Niemann-Pick disease type C, approved in 2024, and ataxia-telangiectasia, approved in September 2026 as its second use.
How much revenue does Aqneursa generate?
IntraBio reported $68 million in sales for 2025, well below the deal’s $2 billion price.
Why is Shionogi buying rare-disease drugmakers?
Shionogi is trying to diversify beyond its traditional infectious-disease business. It bought the ALS drug Radicava for $2.5 billion in April. It is now adding IntraBio’s rare-disease pipeline and expertise on top of that.
Has the Shionogi-IntraBio deal closed?
No. Shionogi had not disclosed a closing date as of the announcement. The acquisition still requires standard regulatory clearance.
What other conditions could IntraBio’s pipeline eventually treat?
IntraBio is running Phase 3 trials for CACNA1A-related disorders. That is a group of rare neurological conditions estimated to affect about 30,000 people in the United States, with no currently approved treatment.
The Ontario Workforce Priority Stream now awards 10 points to candidates earning $80,000 or more, up from a previous top bracket of 8 points, CIC News reports. The change took effect on 5 October 2026 and was announced publicly on 7 October.
Under the “Canadian work experience: earnings history” factor, annual earnings score as follows: $80,000 or more, 10 points (new); $70,000 to $79,999, 8; $50,000 to $69,999, 6; $30,000 to $49,999, 4; under $30,000, 0. Income comes from a Canada Revenue Agency Notice of Assessment issued within the past five years, and the change was applied automatically to affected profiles.
How the stream works
The Ontario Workforce Priority Stream (OWPS) is currently the only route for foreign nationals to seek Ontario provincial nomination for permanent residence. The province revoked all previous pathways on 30 May 2026, launched OWPS on 26 June, unveiled its ranking system on 20 July and opened intake on 4 August.
What is still to come
A second phase will add Priority Healthcare, Entrepreneur and Exceptional Talent streams, with no launch date announced. CIC News cites Ontario’s update page at ontario.ca; check it before acting. Not sure where you stand? Try our visa eligibility checker. Our earlier explainer on Canada work permit processing times may also help.
Ontario OWPS: common questions
What changed in the Ontario Workforce Priority Stream?
A new top earnings bracket: $80,000 or more now scores 10 points instead of 8.
When did it take effect?
5 October 2026, announced on 7 October.
How is income verified?
By a Canada Revenue Agency Notice of Assessment issued within the past five years.
Are other Ontario streams open?
Not yet. OWPS is the only one currently available; three more are planned without dates.
Levi Strauss reported third-quarter results on October 7, 2026. The numbers surprised Wall Street. Net income jumped 39% to $168.6 million. A Levi Strauss tariff refund added 16 cents to earnings per share, the company said. That refund turned what could have been a flat quarter into one of Levi’s strongest in years. The denim maker also raised its full-year profit forecast. Management is betting that steady demand and lower duties will carry the business through the earnings season and into the holidays.
How the Levi Strauss Tariff Refund Changed the Quarter
Levi Strauss booked net revenue of $1.61 billion for the quarter ended August 30, 2026. That is up 4% from a year earlier, and up 5% on an organic basis. The figures come from the company’s own filing with the Securities and Exchange Commission. Diluted earnings per share from continuing operations reached 43 cents, up from 31 cents a year ago. Adjusted EPS hit 48 cents, also well above last year’s 34 cents.
Most of that gain traces back to trade policy, not just stronger sales. Levi’s received refunds tied to tariffs imposed under the International Emergency Economic Powers Act, known as IEEPA. Those refunds added 16 cents to EPS on their own. The company plowed roughly 5 cents of that back into marketing and promotions. That left a net benefit of about 11 cents. Even stripping out the refund entirely, earnings still grew from a year earlier.
Gross margin expanded 450 basis points to 66.2%. Operating margin rose to 13.8% from 10.8%. Nine-month revenue now stands at $4.91 billion, up 9% from the same period in 2025. Those are the kind of margin gains retail investors tend to reward quickly, and Levi’s stock moved on the news.
Why the Refund Lands at a Useful Moment for Apparel Sellers
Tariffs have squeezed clothing companies all year. Levi’s finance chief warned back in April that duties could cost the company roughly $100 million in fiscal 2026. The company spent months offsetting that hit. It raised some prices. It renegotiated with suppliers. It shifted sourcing away from China. A partial refund now reverses some of that earlier pain, and the timing helps. It arrives just as households start back-to-school and holiday shopping, as the company first flagged the tariff pressure to investors back in April.
The timing matters beyond one company’s balance sheet, too. Apparel makers import most of their stock from Asia. Any shift in duty policy ripples through pricing on store shelves worldwide. A refund for Levi’s signals that at least some of this year’s tariff costs were not permanent. Other importers will watch that signal closely as they plan next year’s budgets and pricing strategies.
The Soft Spot Beneath the Levi Strauss Tariff Refund Headline
Not every number in Thursday’s report was rosy. Direct-to-consumer sales, which include company-run stores and e-commerce, rose only 2%. Comparable sales grew just 0.4%. That is a sharp slowdown from the high-single-digit comparable growth Levi’s posted in the same quarter last year. Revenue in the Americas region, Levi’s largest market, rose only 4% overall. Sales inside the United States actually fell 1%.
Europe and Asia carried more of the load this quarter. European revenue rose 4% on a reported basis and 5% organically. Asia grew 5% reported and 10% organically. Wholesale sales, where Levi’s sells through other retailers, rose 6% company-wide. That outpaced growth in Levi’s own stores. The split raises a real question for analysts to press management on. Is the U.S. consumer actually slowing down? Or is Levi’s direct retail business simply losing ground to wholesale partners and resale competitors?
Analysts had mixed reactions to the print. Some noted that the tariff refund and currency swings flattered the headline numbers. Others pointed out that the gross margin gain came from real pricing power, not accounting noise. Levi’s stock swung in early trading as investors weighed both views. Shares ended the session higher, which suggests the market leaned toward the more optimistic read.
The Guidance Levi’s Is Banking On Through the Holidays
Levi Strauss raised its adjusted full-year earnings guidance to a range of $1.54 to $1.56 per share. That is up from $1.46 to $1.52 previously. The company now expects adjusted operating margin of about 12.1%, slightly above its earlier 12% target. Reported revenue growth guidance held at roughly 7%. Organic growth guidance edged up to about 6%.
The company also announced a $100 million accelerated share repurchase program. It kept its quarterly dividend at 16 cents a share. Management said it expects direct-to-consumer comparable sales to return to mid-single-digit growth in the fourth quarter. That recovery still needs to show up in the numbers to justify how investors reacted to Thursday’s report. Levi’s also confirmed it now reports its former Dockers brand as a discontinued operation, following its planned exit from that business earlier this year. The result sits alongside a string of other Q3 2026 corporate reports this week that have largely beaten lowered expectations.
Levi Strauss Earnings: Questions Readers Are Asking
What drove Levi Strauss’s Q3 2026 profit jump?
A mix of higher gross margin, strong international demand, and a one-time tariff refund worth 16 cents per share. Net income rose 39% to $168.6 million.
How much did tariffs cost Levi’s before the refund?
The company had expected roughly $100 million in tariff-related costs for fiscal 2026 when it gave guidance back in April. The October refund offset part of that earlier hit.
Did Levi Strauss raise its full-year guidance?
Yes. It raised adjusted EPS guidance to $1.54 to $1.56 and lifted its adjusted operating margin target to about 12.1%.
Is demand for Levi’s weakening in the United States?
U.S. revenue fell 1% in the quarter. Comparable direct-to-consumer sales grew just 0.4%, well below last year’s pace. Growth came mostly from Europe and Asia instead.
What is Levi Strauss doing with its extra cash?
The company launched a $100 million accelerated share buyback. It also kept its quarterly dividend at 16 cents per share.
When will Levi Strauss report its next results?
The company’s fiscal fourth quarter ends in late November. Results are typically released in January.
